Witness Testimony

Dr. Jean-Marc Sabatier, Research Director at the French National Centre for Scientific Research (CNRS), testified regarding the interaction between the SARS-CoV-2 spike protein and the renin-angiotensin system (RAS). He explained that both viral infection and vaccine-induced spike protein production may bind to the ACE2 receptor, potentially disrupting angiotensin II regulation and leading to overactivation of the AT1R receptor. According to his testimony, such overactivation may contribute to inflammatory, thrombotic, hypertensive, fibrotic, hypoxic, and oxidative stress-related processes across multiple organ systems due to the widespread distribution of the RAS in human tissues.
He further stated that individual susceptibility may vary due to vitamin D status, genetic polymorphisms affecting RAS components, age, sex, and pre-existing comorbidities. He argued that certain structural features of the SARS-CoV-2 spike protein, including receptor-binding domains, facilitating epitopes, the RGD integrin-binding motif, and the furin cleavage site, were known prior to vaccine deployment and may present theoretical risks when used as the primary vaccine antigen. He also raised concerns about immune system dysregulation, including potential impairment of innate and adaptive immune coordination following repeated antigen exposure.
Regarding mRNA vaccine technology, Dr. Sabatier expressed concerns about lipid nanoparticle biodistribution, pseudouridine-modified mRNA stability, potential translation variability, and the possibility of truncated or heterogeneous spike protein production due to manufacturing variability. He stated that alternative vaccine strategies could have included modified spike analogues incapable of ACE2 binding or targeting alternative viral antigens such as nucleocapsid protein. He concluded that greater precaution, longer-term evaluation, and alternative therapeutic approaches should have been prioritized prior to mass vaccination campaigns.